Procter & Gamble Health (Mid Cap) Share Target 2025, 2026 To 2035
|
Procter & Gamble Health Limited |
|||
|
Price: ₹5,511.65 (+1.91%) | ||
| 52 Week Low: ₹4,636.55 52 Week High: ₹5,850.00 |
|||
| Market Capital: 7,962.64 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Procter & Gamble Health Share Price Target For 2025
- 1.1.1: Procter & Gamble Health Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Procter & Gamble Health Share Price Target For 2026
- 1.2.1: Procter & Gamble Health Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Procter & Gamble Health Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Procter & Gamble Health Brief Company Overview
- 4: Procter & Gamble Health Financial Performance
- 4.0.1: Is Procter & Gamble Health A Good Buy For Long Term?
Procter & Gamble Health, a Mid Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 22.2% returns in 5-year with 18.3% profit margin.
To predict the Procter & Gamble Health's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Procter & Gamble Health Share Price Target For 2025
The line chart displays the monthly closing prices of Procter & Gamble Health with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Procter & Gamble Health shares in 2025, see the table below.
Procter & Gamble Health Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 5967.9 (+8.27%) | Price Action: Jun 2021 High |
| 2025 Target 2 | 5803.95 (+5.3%) | Price Action: 07 Nov 2024 High |
| 2025 Target 1 | 5719.2 (+3.76%) | Price Action: 13 Dec 2024 High |
| Current Price | 5511.65 | Procter & Gamble Health's share price as of 23 Jan 2025 |
| Stop Loss 1 | 5425.05 (-1.58%) | Price Action: 12 Sep 2024 High |
| Stop Loss 2 | 5370.1 (-2.57%) | Price Action: 23 Jan 2025 Low |
| Stop Loss 3 | 5315.0 (-3.57%) | Price Action: 07 Feb 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Procter & Gamble Health is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹5336.01 serves as the nearest technical reference point.
Historical Returns: 3-month: +4.55% | 6-month: +4.21% | 1-year: +9.59%
Procter & Gamble Health Share Price Target For 2026
The line chart displays the monthly closing prices of Procter & Gamble Health with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Procter & Gamble Health shares in 2026, see the table below.
Procter & Gamble Health Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 6800.54 (+23.38%) | Fibonacci Extension Level 82.00% |
| 2026 Target 2 | 6635.91 (+20.39%) | Fibonacci Extension Level 150.00% |
| 2026 Target 1 | 6531.76 (+18.5%) | Fibonacci Extension Level 64.90% |
| Current Price | 5511.65 | Procter & Gamble Health's share price as of 23 Jan 2025 |
| Stop Loss 1 | 5277.95 (-4.25%) | Price Action: 03 Jan 2025 High |
| Stop Loss 2 | 5225.0 (-5.21%) | Price Action: 23 Jan 2024 Low |
| Stop Loss 3 | 5171.95 (-6.17%) | Price Action: Feb 2022 High |
Long-Term Technical Outlook
52-Week Range Analysis: Procter & Gamble Health is currently trading at 72.1% of its 52-week range (₹4636.55 - ₹5850).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +9.59% | 3-year: +6.91% | 5-year: +22.23%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Procter & Gamble Health Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹5,511.65 | ||
| 2025 | ₹6,495.37 | +17.84% | ₹6,592.80 |
| 2026 | ₹7,790.43 | +19.93% | ₹7,907.29 |
| 2027 | ₹8,755.25 | +12.38% | ₹8,886.58 |
| 2028 | ₹10,288.63 | +17.51% | ₹10,442.96 |
| 2029 | ₹11,903.67 | +15.69% | ₹12,082.23 |
| 2030 | ₹14,075.79 | +18.24% | ₹14,286.93 |
| 2031 | ₹14,540.04 | +3.29% | ₹14,758.14 |
| 2032 | ₹16,262.03 | +11.84% | ₹16,505.96 |
| 2033 | ₹17,021.16 | +4.66% | ₹17,276.48 |
| 2034 | ₹20,050.35 | +17.79% | ₹20,351.11 |
| 2035 | ₹21,629.07 | +7.87% | ₹21,953.51 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Procter & Gamble Health Brief Company Overview
Procter & Gamble Health Limited: A Global Healthcare Pioneer Established in 1967, Procter & Gamble Health Limited (formerly Merck Limited) is a leading manufacturer and marketer of pharmaceuticals and chemical products in India and worldwide. Headquartered in Mumbai, the...
company boasts a diverse product portfolio. Key Products and Services: Over-the-counter products Vitamins, minerals, and supplements Market Presence: Procter & Gamble Health Limited has a strong presence in the healthcare industry, with its products available in multiple countries. Reputation and Commitment: The company is renowned for its high-quality products and commitment to improving health outcomes. Procter & Gamble Health Limited's mission is to "make a meaningful difference in the lives of our consumers by providing them with innovative and affordable healthcare solutions."Procter & Gamble Health Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 7,962.64 Crore | Market valuation of Procter & Gamble Health's shares. |
| Revenue (TTM) | 1,168.56 Crore | Total revenue generated by Procter & Gamble Health over the past twelve months. |
| Net Income (TTM) | +214.01 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +25.02% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +18.3% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-21.3% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-21.3% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
1.34 | Company's total debt divided by total shareholder equity. |
| Total Debt | 10.8 Crore | Sum of Procter & Gamble Health's current & long-term financial obligations. |
| Total Cash | 425.56 Crore | Total amount of liquid funds available to Procter & Gamble Health. |
| Beta | 0.44 | Beta is less than 1 indicating that the Procter & Gamble Health's price is less volatile than the market. |
Is Procter & Gamble Health A Good Buy For Long Term?
Procter & Gamble Health is a midcap stock with a moderate market capitalization. Over the past year, the company has seen a decline in earnings and revenue growth. However despite this, it maintains a healthy profit margin of 18.31%. Financially, the company has a manageable debt of 10.8 Crore and a strong cash balance of 425.56 Crore. Considering these factors, Procter & Gamble Health may be considered an average buy for long-term investment, with potential for future growth.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
